Abstract Endocrine treatment is the first-line therapy in hormone-sensitive metastatic breast cancer while chemotherapy is the first option in tumors refractory to endocrine therapy and in hormone-negative disease. Optimal duration, efficacy and safety of a maintenance endocrine therapy or chemotherapy after an induction treatment are still a matter of debate. We performed a literature review to identify studies regarding maintenance hormonal and chemotherapy treatments in metastatic breast cancer. We analyzed data relating to efficacy (improvement of progression-free survival and overall survival) and safety (symptoms relief and quality of life [QoL]). Maintenance endocrine therapy could prolong progression-free survival with a better control of symptoms and improving QoL. Maintenance chemotherapy prolong the response to a previous treatment, worsening the QoL, except for metronomic capecitabine.

Rossi, S., Schinzari, G., Basso, M., Strippoli, A., Dadduzio, V., D'argento, E., Cassano, A., Barone, C. A., Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review., <<FUTURE ONCOLOGY>>, 2016; (May): 1299-1307 [http://hdl.handle.net/10807/94290]

Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.

Rossi, Sabrina;Schinzari, Giovanni;Basso, Michele;Strippoli, Antonia;Dadduzio, Vincenzo;D'Argento, Ettore;Cassano, Alessandra;Barone, Carlo Antonio
2016

Abstract

Abstract Endocrine treatment is the first-line therapy in hormone-sensitive metastatic breast cancer while chemotherapy is the first option in tumors refractory to endocrine therapy and in hormone-negative disease. Optimal duration, efficacy and safety of a maintenance endocrine therapy or chemotherapy after an induction treatment are still a matter of debate. We performed a literature review to identify studies regarding maintenance hormonal and chemotherapy treatments in metastatic breast cancer. We analyzed data relating to efficacy (improvement of progression-free survival and overall survival) and safety (symptoms relief and quality of life [QoL]). Maintenance endocrine therapy could prolong progression-free survival with a better control of symptoms and improving QoL. Maintenance chemotherapy prolong the response to a previous treatment, worsening the QoL, except for metronomic capecitabine.
Inglese
Rossi, S., Schinzari, G., Basso, M., Strippoli, A., Dadduzio, V., D'argento, E., Cassano, A., Barone, C. A., Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review., <>, 2016; (May): 1299-1307 [http://hdl.handle.net/10807/94290]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/94290
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? ND
social impact